Cost‐Effectiveness of Tenofovir as First‐Line Antiretroviral Therapy in India | Zendy

Melissa A. Bender | Zendy; Nagalingeswaran Kumarasamy | Zendy; Kenneth H. Mayer | Zendy; Bingxia Wang | Zendy; Rochelle P. Walensky | Zendy; Timothy Flanigan | Zendy; Bruce R. Schackman | Zendy; Callie A. Scott | Zendy; Zhigang Lu | Zendy; Kenneth A. Freedberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost‐Effectiveness of Tenofovir as First‐Line Antiretroviral Therapy in India

Author(s) -

Melissa A. Bender,

Nagalingeswaran Kumarasamy,

Kenneth H. Mayer,

Bingxia Wang,

Rochelle P. Walensky,

Timothy Flanigan,

Bruce R. Schackman,

Callie A. Scott,

Zhigang Lu,

Kenneth A. Freedberg

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/649884

Subject(s) - stavudine , zidovudine , lamivudine , medicine , tenofovir , reverse transcriptase inhibitor , nevirapine , abacavir , kharif crop , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , viral load , viral disease , statistics , mathematics , virus , hepatitis b virus , field experiment

World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research